Cantor Fitzgerald cuts Gossamer Bio stock rating after trial miss

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Asia stocks sink; Japan, S.Korea lead losses as Iran crisis worsens Gold slides 4%, wipes out 2026 gains as Iran crisis keeps rate fears in play Goldman raises Brent forecasts again, sees higher oil prices for longer Spike in oil prices seen as ’a clear risk for consumer equities’ (South Africa Philippines Nigeria) Cantor Fitzgerald cuts Gossamer Bio stock rating after trial miss By Analyst Ratings Published 03/23/2026, 04:03 AM Cantor Fitzgerald cuts Gossamer Bio stock rating after trial miss 0 GOSS -6.64% Investing.com - Cantor Fitzgerald downgraded Gossamer Bio Inc. (NASDAQ:GOSS) to Neutral from Overweight following a negative Phase 3 trial readout for seralutinib in pulmonary arterial hypertension. The stock, currently trading at $0.42 with a market cap of $99 million, has plunged 86% year-to-date. The downgrade comes after the PROSERA trial failed to meet its endpoints, leaving an unclear regulatory path forward for the drug candidate. Management plans to present the dataset to the Food and Drug Administration. The company is requesting a Type C meeting with the FDA expected to occur in June, with clarity on a potential path forward anticipated by July. Enrollment in the Phase 3 SERANATA study for pulmonary hypertension associated with interstitial lung disease remains paused. Cantor Fitzgerald noted the drug shows a signal in the data but said the firm lacks conviction on whether Gossamer Bio has a strong case for commercialization. The firm is moving to the sidelines until more clarity emerges later this year. InvestingPro data reveals the company is quickly burning through cash with negative free cash flow of $171 million, though liquid assets still exceed short-term obligations. Gossamer Bio develops therapies for immunology, inflammation and oncology conditions. In other recent news, Gossamer Bio has faced a series of downgrades from major analyst firms following disappointing results from its Phase...